The COVID-19 pandemic is acutely threatening access to essential health services,
including abortion [1]. Across all fields of medicine, changes in practice models are …

Objective This guideline reviews the evidence relating to the provision of first-trimester
medical induced abortion, including patient eligibility, counselling, and consent; evidence …

“Very early medical abortion”(VEMA) refers to medical abortion (with mifepristone and
misoprostol) before intrauterine pregnancy is visualized on ultrasound. Our aim is to present …

OBJECTIVE: To compare immediate initiation with delayed initiation of medication abortion
among patients with an undesired pregnancy of unknown location. METHODS: This …

Introduction Women are increasingly presenting for abortion at very early gestation.
However, providers may be reluctant to conduct abortion at this stage as they may be …

Mifepristone approval by the United States (US) Food and Drug Administration in 2000
revolutionized abortion care in this country. In 2020, 53% of people having facility-based …

Objective To assess the efficacy and safety of medical termination of pregnancy (MTOP)
when no intrauterine pregnancy (IUP) is confirmed on ultrasound. Design Retrospective …

Introduction Requests for termination of pregnancy (TOP) at very early gestation (≤ 6
weeks) can prove challenging for abortion services as the ultrasound feature usually …

Objective To compare days to diagnosis of pregnancy location for same-day medication
abortion and same-day uterine aspiration with delayed treatment (expectant management) …

Objectives The ideal assessment after mifepristone and misoprostol for undesired
pregnancy of unknown location (PUL) is unknown. Study design We prospectively followed …